Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company’s lead technology, MetaMx, targets brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma.